Tumor-infiltrating lymphocytes and pathologic complete response among the patients with HER2 positive breast cancer receiving neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab (TCHP): Single center experience

被引：0
|
作者：
Ha, J. [1 ]
Kim, J. E. [1 ]
Jeong, J. H. [1 ]
Ahn, J-H. [1 ]
Jung, K. H. [1 ]
Lee, H. J. [2 ]
Gong, G. [2 ]
Chae, E. Y. [3 ,4 ]
Kim, H. H. [3 ,4 ]
Chung, I. Y. [5 ]
Ko, B. S. [5 ]
Kim, S-B. [1 ]
机构：
[1] Univ Ulsan, Dept Oncol, Asan Med Ctr, Coll Med, Seoul, South Korea
[2] Univ Ulsan, Dept Pathol, Asan Med Ctr, Coll Med, Seoul, South Korea
[3] Univ Ulsan, Asan Med Ctr, Dept Radiol, Coll Med, Seoul, South Korea
[4] Univ Ulsan, Asan Med Ctr, Res Inst Radiol, Coll Med, Seoul, South Korea
[5] Univ Ulsan, Dept Surg, Asan Med Ctr, Coll Med, Seoul, South Korea
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
30P
引用
收藏
页码：10 / 10
页数：1
相关论文
共 50 条
  • [1] Impact of Dose Intensity on Pathologic Complete Response Rate in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Docetaxel, Carboplatin, Trastuzumab and Pertuzumab (TCHP)
    Dat Le
    Craig Vargo
    Stephanie Collins
    Nicole Williams
    Marilly Palettas
    Michael Berger
    Targeted Oncology, 2022, 17 : 167 - 175
  • [2] Impact of Dose Intensity on Pathologic Complete Response Rate in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Docetaxel, Carboplatin, Trastuzumab and Pertuzumab (TCHP)
    Le, Dat
    Vargo, Craig
    Collins, Stephanie
    Williams, Nicole
    Palettas, Marilly
    Berger, Michael
    TARGETED ONCOLOGY, 2022, 17 (02) : 167 - 175
  • [3] Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Neoadjuvant Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab
    Ha, Joo Young
    Kim, Jeong Eun
    Lee, Hee Jin
    Jeong, Jae Ho
    Ahn, Jin-Hee
    Jung, Kyung Hae
    Gong, Gyungyub
    Chae, Eun Young
    Kim, Hak Hee
    Chung, Il Yong
    Ko, Beom Seok
    Kim, Sung-Bae
    JOURNAL OF BREAST CANCER, 2021, 24 (04) : 359 - 366
  • [4] Pathologic complete response rate according to the carboplatin dose in patients with non-metastatic HER2+breast cancer treated with neoadjuvant docetaxel/carboplatin/trastuzumab/pertuzumab (TCHP)
    Ji, Jung Hwan
    Bae, Soong June
    Kim, Seul-Gi
    Kim, Min Hwan
    Kim, Gun-Min
    Sohn, Joohyuk
    Kim, Jee Hung
    Ahn, Sung Gwe
    Jeong, Joon
    CANCER RESEARCH, 2022, 82 (04)
  • [5] Real Would Evidence (RWE) of neoadjuvant docetaxel/carboplatin/trastuzumab/pertuzumab (TCHP) in patients with HER2 positive early or locally advanced breast cancer treated Single institutional experience
    Kim, Ji-Yeon
    Nam, Seok Jin
    Kim, Seok Won
    Yu, Jonghan
    Chae, Byung Joo
    Lee, Se Kyung
    Ryu, Jai Min
    Ahn, Jin Seok
    Im, Young-Hyuck
    Park, Yeon Hee
    CANCER RESEARCH, 2021, 81 (04)
  • [6] Tumor infiltrating lymphocytes as a predictor of pathologic complete response to neoadjuvant therapy in HER2 positive breast cancer
    Chargoy, Alberto Monroy
    Verduzco-Aguirre, Haydee Cristina
    Chargoy, Javier Monroy
    Espinosa-Fernandez, Jose Rodrigo
    Ojeda, Jesus Antonio Martinez
    Cabrera-Galeana, Paula
    CANCER RESEARCH, 2024, 84 (09)
  • [7] Carboplatin dose capping affects pCR rate in HER2-positive breast cancer patients treated with neoadjuvant Docetaxel, Carboplatin, Trastuzumab, Pertuzumab (TCHP)
    Howell, Sacha J.
    Coe, Faye
    Wang, Xin
    Horsley, Laura
    Ekholm, Maria
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 184 (02) : 481 - 489
  • [8] Carboplatin dose capping affects pCR rate in HER2-positive breast cancer patients treated with neoadjuvant Docetaxel, Carboplatin, Trastuzumab, Pertuzumab (TCHP)
    Sacha J. Howell
    Faye Coe
    Xin Wang
    Laura Horsley
    Maria Ekholm
    Breast Cancer Research and Treatment, 2020, 184 : 481 - 489
  • [9] Real World Evidence of Neoadjuvant Docetaxel/Carboplatin/Trastuzumab/Pertuzumab (TCHP) in Patients with HER2-Positive Early or Locally Advanced Breast Cancer: A Single-Institutional Clinical Experience
    Kim, Ji-Yeon
    Nam, Seok Jin
    Lee, Jeong Eon
    Yu, Jonghan
    Chae, Byung Joo
    Lee, Se Kyung
    Ryu, Jai Min
    Ahn, Jin Seok
    Im, Young-Hyuck
    Kim, Seok Won
    Park, Yeon Hee
    CANCER RESEARCH AND TREATMENT, 2022, 54 (04): : 1091 - 1098
  • [10] Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience
    Singh, Jasmeet C.
    Mamtani, Anita
    Barrio, Andrea
    Morrow, Monica
    Sugarman, Steven
    Jones, Lee W.
    Yu, Anthony F.
    Argolo, Daniel
    Smyth, Lilian M.
    Modi, Shanu
    Schweber, Sarah
    Boafo, Camilla
    Patil, Sujata
    Norton, Larry
    Baselga, Jose
    Hudis, Clifford A.
    Dang, Chau
    ONCOLOGIST, 2017, 22 (02): : 139 - 143
12345